Results 81 to 90 of about 30,927 (236)

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

MedComm – Oncology, Volume 4, Issue 3, September 2025.
Immune checkpoints in tumor immunotherapy. Ligand binding to the receptor inhibits immune cell function, promotes tumor cell immune escape, and suppresses the immune response. The pathways of action are VISTA‐IGSF11, TIM‐3‐Ceacam1, CD47‐SIRPα, CTLA‐4‐CD80/CD86, PD‐L1‐PD‐1, MHC‐1‐LILRB, and CD24 ‐ Siglec ‐10. There are also other immune checkpoints such
Han Sun, Dan Huang, Huiling Zhang, Mingyuan Dong, Simiao Wang, Man Sun, Jiayi Liu, Yiqi Wang, Xiaojie Qu, Xuefeng Li, Zhaogang Yang   +10 more
wiley   +1 more source

BTK inhibitor ibrutinib in CLL and mantle cell lymphoma [PDF]

, 2013
Jame Abraham, Matt Stenger
openalex   +1 more source

Go for Gold: Development of a Scalable Synthesis of [1‐(Ethoxycarbonyl)cyclopropyl] Triphenylphosphonium Tetrafluoroborate, a Key Reagent to Explore Covalent Monopolar Spindle 1 Inhibitors

ChemistryOpen, Volume 14, Issue 9, September 2025.
[1‐(Ethoxycarbonyl)cyclopropyl] triphenylphosphonium tetrafluoroborate is a limiting key reagent for synthesis of the tricyclic 5,6‐dihydropyrimido[5,4‐e]indolizine and related scaffolds, which are central to First‐in‐Class covalent inhibitors of the protein kinase monopolar spindle 1/threonine tyrosine kinase (TTK).
Leon Rebhan, Rebekka Fürst, Dieter Schollmeyer, Ricardo A. M. Serafim, Matthias Gehringer   +4 more
wiley   +1 more source

Ibrutinib: a force with a dark side? [PDF]

Blood, 2016
In this issue of Blood, Martin et al report poor outcomes for ibrutinib-refractory patients with mantle cell lymphoma (MCL). MCL, an uncommon B-cell lymphoma driven by dysregulated cyclin D1, responds well to initial therapy but is destined to relapse.
openaire   +3 more sources

Tandem combination of ASCT and CAR T‐cell therapy in highly refractory CNS lymphomas

British Journal of Haematology, EarlyView.
Lydia Montes, Sylvain Choquet, Madalina Uzunov, Véronique Morel, Marine Baron, Damien Roos‐Weil, Magalie Joris, Caroline Delette, Delphine Lebon, Nabih Azar, Carole Metz, Lucia Nichelli, Magali Le Garff‐Tavernier, Clémentine Boccon‐Gibod, Claire Lacan, Laetitia Souchet, Khê Hoang‐Xuan, Carole Soussain, Inès Boussen, Caroline Houillier   +19 more
wiley   +1 more source

Lymphoid Malignancies in Ataxia–Telangiectasia: Experience with Novel Targeted Therapies

Pediatric Blood &Cancer, Volume 72, Issue 9, September 2025.
ABSTRACT Patients with ataxia–telangiectasia (AT) face unique challenges in managing lymphoid malignancies due to heightened sensitivity to chemotherapy and radiation, requiring alternative treatment strategies. This report presents three cases demonstrating the successful integration of targeted therapies: ibrutinib for diffuse large B‐cell lymphoma ...
Samanta Catueno, Ramya Ramakrishnan, Sarah Elitzur, Miriam B. Garcia, David McCall, Cesar Nunez, Michael Roth, Alessandra Ferrajoli, Branko Cuglievan, Amber Gibson   +9 more
wiley   +1 more source

The expression and signalling patterns of CD180 toll like receptor in Chronic Lymphocytic Leukaemia (CLL) [PDF]

, 2019
Chronic lymphocytic leukaemia (CLL) is characterised by a progressive accumulation of mature CD5+CD20+CD23+ lymphocytes. Despite the remarkable progress in our understanding of the immunobiology of CLL, the aetiology of the disease remains unknown.
Sayed, U., Sayed, U.
core  

Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR‐T Cells Against B‐Cell Lymphoma

Cancer Science, Volume 116, Issue 9, Page 2388-2399, September 2025.
In the tumor microenvironment, selinexor suppresses tumor cell growth and prevents macrophages from polarizing to M2 populations. The lower concentration of selinexor decreases CAR‐T cell exhaustion, enhances its cytotoxicity, and upregulates NGFR expression to prompt CAR‐T cell proliferation.
Wenjing Luo, Jia Xu, Chenggong Li, Lu Tang, Yingying Li, Xindi Wang, Zhuolin Wu, Yinqiang Zhang, Heng Mei, Yu Hu   +9 more
wiley   +1 more source

CXCR4 WHIM‐like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88^L265P‐directed survival signalling in Waldenström macroglobulinaemia cells [PDF]

, 2014
Yang Cao, Zachary R. Hunter, Xia Liu, Lian Xu, Guang Yang, Jie Chen, Nickolas Tsakmaklis, Sandra Kanan, Jorge J. Castillo, Steven P. Treon   +9 more
openalex   +1 more source

Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors

Internal Medicine Journal, Volume 55, Issue 9, Page 1556-1569, September 2025.
ABSTRACT Background Bruton's tyrosine kinase inhibitors (BTKi) reduce mortality and morbidity in chronic lymphocytic leukaemia (CLL) but have an association with cardiotoxicities, including hypertension, atrial fibrillation (AF), ventricular arrhythmias (VA) and bleeding.
Mary Ann Anderson, Farrukh T. Awan, Leanne Berkahn, Kyle Crassini, Hui‐Peng Lee, Paula Marlton, Stephen P. Mulligan, Mark Nolan, Constantine Tam, Aaron L. Sverdlov   +9 more
wiley   +1 more source